SOBERANA 02

Phase 1

• Conditions: SARS Virus; Prevention of COVID-19; COVID-19; SARS-CoV2; Disease Prevention; Coronavirus Infections; Coronaviridae Infections; Betacoronavirus

• Registration Number: RPCEC00000340
• Lead Sponsor: Finlay Vaccine Institute (IFV)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-27
• Study Completion: 2021-02-26
• Results First Posted: 2021-03-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Subjects who give their informed consent to participate in the study in writing.
2. Subjects aged between 19 and 59 years.
3. Women of childbearing potential use safe contraceptive methods during the study.
4. General, regional and apparatus physical examination: normal or without clinically significant alterations.
5. Laboratory results within or outside the range of reference values ??but not clinically significant.

Exclusion Criteria

1. Subjects with acute febrile or infectious disease in the 7 days prior to the administration of the vaccine or at the time of its application.
2. Subjects with antimicrobial treatment in the 7 days prior to the administration of the vaccine.
3. Subjects with Weight Loss (BMI <18.5) and Obesity (BMI = 30.0)
4. Subjects with chronic non-communicable diseases not controlled according to clinical or laboratory criteria (eg bronchial asthma, chronic obstructive pulmonary disease, diabetes mellitus, thyroid diseases, ischemic heart disease, arterial hypertension, psychiatric, neurological, hemolymphopoietic system disease ).
5. Subjects with congenital or acquired immune system disease.
6. Subjects with a history of unresolved neoplastic disease.
7. Subjects with a personal history of liver or kidney failure.
8. Subjects with a history of substance abuse within the past 30 days or substance addictive illness, except withdrawal and smoking.
9. Subjects with diminished mental faculties for decision making.
10. Subjects with a history of severe allergic disease (anaphylactic shock, angioneurotic edema, glottis edema, severe urticaria).
11. Subjects with a history of hypersensitivity to thiomersal or to some of the components of the formulation.
12. Subjects with a history of SARS and COVID-19 who meet any of the following criteria:
a) Previous or current history of SARS-CoV-2 infection.
b) Be declared in the category of contact or suspect at the time of inclusion
c) Subject with positive test for Anti-SARS-CoV-2 Antibodies.
d) Subject with positive PCR at the time of inclusion.
13. Participation in another clinical trial in the last 3 months.
14. Application of vaccines containing tetanus toxoid in the last 3 months.
15. Application of other vaccines in the last 30 days.
16. Treatment with immunomodulators in the last 30 days, considering steroids (except topical and inhaled), cytostatics, interferon, immunoferon, transfer factor, monoclonal antibody, Biomodulin T, any ganmaglobulin, Levamisole, Heberferon, thymosin) or other drugs with action immunomodulatory. In addition, those people who, due to their underlying disease, require immunomodulatory treatment during the development of the study.
17. Transfusion of blood or blood products in the last 3 months.
18. Subjects with difficulties in attending the planned follow-up consultations.
19. Splenectomy or splenic dysfunction.
20. Pregnancy, puerperium or lactation.
21. Subjects with tattoos in the deltoid region on both arms.
22. Subjects with positive results for HIV, Hepatitis B surface antigen, Hepatitis C Antibody, and VDRL serology.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) Serious Adverse Events-SAE (It will measure as: -Occurrence of the SAE (Yes, No), - Duration (Time from start date until end date of event), -Description of the event, Result (Recovered, Recovered with squeals, Persists, Death, Unknown), - Causality (Causal association consistent with vaccination, Undetermined, Inconsistent causal association with vaccination, not classifiable). Measurement time: daily for 28 days after each dose.